Skye Bioscience (SKYE) announced the Board has appointed independent director Paul Grayson as Skye’s new Chairman of the Board, effective October 25, 2024. Grayson currently serves as a member of Skye’s Audit, Compensation and Nominating and Corporate Governance Committees. Punit Dhillon, Skye’s Chief Executive Officer, will continue to serve as a member of the Board.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SKYE:
- Skye Bioscience Approves Incentive Plan Amendments and Leadership Changes
- Rising High: RIV Capital, Cansortium launch MOODS brand in New York
- Skye Bioscience started with an Outperform at Scotiabank on nimacimab potential
- Skye Bioscience initiated with an Outperform at Scotiabank
- Skye Bioscience provides perspectives on prospects for nimacimab